138 related articles for article (PubMed ID: 33489901)
21. Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.
Kim SJ; Kim JS; Kim SW; Yun SJ; He J; Brantley E; Fan D; Strickner P; Lehembre F; Regenass U; Fidler IJ
Transl Oncol; 2012 Feb; 5(1):39-47. PubMed ID: 22348175
[TBL] [Abstract][Full Text] [Related]
22. Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts.
Cipriani P; Di Benedetto P; Ruscitti P; Verzella D; Fischietti M; Zazzeroni F; Liakouli V; Carubbi F; Berardicurti O; Alesse E; Giacomelli R
Arthritis Res Ther; 2015 Sep; 17(1):247. PubMed ID: 26357964
[TBL] [Abstract][Full Text] [Related]
23. Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease.
Tullos NA; Stewart NJ; Davidovich R; Chade AR
Nephrol Dial Transplant; 2015 Apr; 30(4):584-93. PubMed ID: 25438341
[TBL] [Abstract][Full Text] [Related]
24. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells.
Spinella F; Rosanò L; Di Castro V; Natali PG; Bagnato A
J Biol Chem; 2002 Aug; 277(31):27850-5. PubMed ID: 12023962
[TBL] [Abstract][Full Text] [Related]
25. Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats.
Kunita-Takanezawa M; Abe K; Hirooka Y; Kuwabara Y; Hirano K; Oka M; Sunagawa K
J Cardiovasc Pharmacol; 2014 Nov; 64(5):473-80. PubMed ID: 25084082
[TBL] [Abstract][Full Text] [Related]
26. Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.
Kim SJ; Lee HJ; Kim MS; Choi HJ; He J; Wu Q; Aldape K; Weinberg JS; Yung WK; Conrad CA; Langley RR; Lehembre F; Regenass U; Fidler IJ
Clin Cancer Res; 2015 Oct; 21(20):4630-41. PubMed ID: 26106074
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia regulates angeogenic-osteogenic coupling process via up-regulating IL-6 and IL-8 in human osteoblastic cells through hypoxia-inducible factor-1α pathway.
Niu X; Chen Y; Qi L; Liang G; Wang Y; Zhang L; Qu Y; Wang W
Cytokine; 2019 Jan; 113():117-127. PubMed ID: 29934049
[TBL] [Abstract][Full Text] [Related]
28. Targeting HIF-1α and VEGF by lentivirus-mediated RNA interference reduces liver tumor cells migration and invasion under hypoxic conditions.
Chen J; Lai L; Liu S; Zhou C; Wu C; Huang M; Lin Q
Neoplasma; 2016; 63(6):934-940. PubMed ID: 27565331
[TBL] [Abstract][Full Text] [Related]
29. Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis.
Wang J; Li G; Wang Y; Tang S; Sun X; Feng X; Li Y; Bao G; Li P; Mao X; Wang M; Liu P
Oncotarget; 2015 Dec; 6(42):44579-92. PubMed ID: 26625311
[TBL] [Abstract][Full Text] [Related]
30. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade.
Spinella F; Garrafa E; Di Castro V; Rosanò L; Nicotra MR; Caruso A; Natali PG; Bagnato A
Cancer Res; 2009 Mar; 69(6):2669-76. PubMed ID: 19276384
[TBL] [Abstract][Full Text] [Related]
31. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
[TBL] [Abstract][Full Text] [Related]
32. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment.
Ge Y; Yoon SH; Jang H; Jeong JH; Lee YM
Phytomedicine; 2020 Nov; 78():153318. PubMed ID: 32896707
[TBL] [Abstract][Full Text] [Related]
33. Chlorogenic acid inhibits hypoxia-induced angiogenesis via down-regulation of the HIF-1α/AKT pathway.
Park JJ; Hwang SJ; Park JH; Lee HJ
Cell Oncol (Dordr); 2015 Apr; 38(2):111-8. PubMed ID: 25561311
[TBL] [Abstract][Full Text] [Related]
34. Wogonin inhibits tumor angiogenesis via degradation of HIF-1α protein.
Song X; Yao J; Wang F; Zhou M; Zhou Y; Wang H; Wei L; Zhao L; Li Z; Lu N; Guo Q
Toxicol Appl Pharmacol; 2013 Sep; 271(2):144-55. PubMed ID: 23707765
[TBL] [Abstract][Full Text] [Related]
35. Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma.
Russignan A; Spina C; Tamassia N; Cassaro A; Rigo A; Bagnato A; Rosanò L; Bonalumi A; Gottardi M; Zanatta L; Giacomazzi A; Scupoli MT; Tinelli M; Salvadori U; Mosna F; Zamò A; Cassatella MA; Vinante F; Tecchio C
Br J Haematol; 2017 Sep; 178(5):781-793. PubMed ID: 28597546
[TBL] [Abstract][Full Text] [Related]
36. Angiogenesis and multiple myeloma.
Giuliani N; Storti P; Bolzoni M; Palma BD; Bonomini S
Cancer Microenviron; 2011 Dec; 4(3):325-37. PubMed ID: 21735169
[TBL] [Abstract][Full Text] [Related]
37. Ras induction of superoxide activates ERK-dependent angiogenic transcription factor HIF-1alpha and VEGF-A expression in shock wave-stimulated osteoblasts.
Wang FS; Wang CJ; Chen YJ; Chang PR; Huang YT; Sun YC; Huang HC; Yang YJ; Yang KD
J Biol Chem; 2004 Mar; 279(11):10331-7. PubMed ID: 14681237
[TBL] [Abstract][Full Text] [Related]
38. The endothelin-1-driven tumor-stroma feed-forward loops in high-grade serous ovarian cancer.
Tocci P; Roman C; Sestito R; Caprara V; Sacconi A; Molineris I; Tonon G; Blandino G; Bagnato A
Clin Sci (Lond); 2024 Jun; ():. PubMed ID: 38884602
[TBL] [Abstract][Full Text] [Related]
39. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.
Vaiou M; Pangou E; Liakos P; Sakellaridis N; Vassilopoulos G; Dimas K; Papandreou C
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2141-58. PubMed ID: 27530445
[TBL] [Abstract][Full Text] [Related]
40. A new anti-angiogenic small molecule, G0811, inhibits angiogenesis via targeting hypoxia inducible factor (HIF)-1α signal transduction.
Kim KH; Jung HJ; Kwon HJ
Biochem Biophys Res Commun; 2013 Nov; 441(2):399-404. PubMed ID: 24161739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
